May 30- June 3, 2025
McCormick Place Convention Center
Chicago, IL
Booth #23093
Connect with Caris Life Sciences at ASCO 2025
Join Caris Life Sciences® at the upcoming American Society of Clinical Oncology® (ASCO) Annual Meeting in Chicago, IL. Visit our team at booth #23093 to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution.
Caris’ ASCO 2025 Abstracts Demonstrate the Clinical Value of Comprehensive Molecular Profiling
Caris and its collaborators within the Caris Precision Oncology Alliance™ (POA) had 37 abstracts accepted for presentation at the 2025 American Society of Clinical Oncology® (ASCO) Annual Meeting, including one oral abstract and 36 posters. These studies, covering 16 tumor types, demonstrate the power of Caris’ comprehensive clinicogenomic database to enable novel insights into cancer that could profoundly affect a patient’s diagnosis, prognosis, care plan, and response to treatment.
“This year’s ASCO abstracts highlight the growing clinical value of integrated molecular profiling and real-world data, particularly as AI tools transform how we diagnose and treat cancer. The data from our internal and collaborative studies show that we are entering a new era of precision oncology, where every data point can support smarter, more personalized decision-making.”
– Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD.
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Profile
MI Profile™ comprehensive testing delivers whole exome sequencing (WES – DNA) and whole transcriptome sequencing (WTS – RNA) for 23,000+ genes, as well as protein analysis and AI-predictive algorithms. The test is designed to reveal a complete molecular blueprint that can guide more precise and individualized treatment decisions that help improve patient outcomes.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Complete Molecular Intelligence Report
The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent clinical trial opportunities.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.